Phase II study of rituximab and gemcitabine in patients with relapsed or refractory diffuse large B-cell lymphoma: Hoosier Oncology Group LYM03-64.

Trial Profile

Phase II study of rituximab and gemcitabine in patients with relapsed or refractory diffuse large B-cell lymphoma: Hoosier Oncology Group LYM03-64.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2014

At a glance

  • Drugs Gemcitabine; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2007 Status changed from in progress to discontinued (due to lack of response at the first efficacy analysis).
    • 27 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top